vs
PagerDuty, Inc.（PD）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是PagerDuty, Inc.的1.0倍（$127.1M vs $124.5M），再鼎医药同比增速更快（17.1% vs 4.7%），PagerDuty, Inc.自由现金流更多（$24.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 5.9%）
PagerDuty是一家美国云计算企业，主打面向IT运维部门的SaaS事件管理平台，可帮助企业实时响应运维异常、快速定位并处理故障，保障业务系统稳定运行，目前已成为全球IT运维领域广受认可的数字化解决方案服务商。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PD vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.0倍
$124.5M
营收增速更快
ZLAB
高出12.4%
4.7%
自由现金流更多
PD
多$50.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
5.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $124.5M | $127.1M |
| 净利润 | $161.6M | — |
| 毛利率 | 85.3% | 51.0% |
| 营业利润率 | 6.5% | -54.6% |
| 净利率 | 129.7% | — |
| 营收同比 | 4.7% | 17.1% |
| 净利润同比 | 2827.7% | — |
| 每股收益（稀释后） | $1.69 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PDZLAB
| Q4 25 | $124.5M | $127.1M | ||
| Q3 25 | $123.4M | $115.4M | ||
| Q2 25 | $119.8M | $109.1M | ||
| Q1 25 | $121.4M | $105.7M | ||
| Q4 24 | $118.9M | $108.5M | ||
| Q3 24 | $115.9M | $101.8M | ||
| Q2 24 | $111.2M | $100.1M | ||
| Q1 24 | $111.1M | $87.1M |
净利润PDZLAB
| Q4 25 | $161.6M | — | ||
| Q3 25 | $9.6M | $-36.0M | ||
| Q2 25 | $-7.2M | $-40.7M | ||
| Q1 25 | $-8.8M | $-48.4M | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-10.9M | $-41.7M | ||
| Q2 24 | $-17.1M | $-80.3M | ||
| Q1 24 | $-28.2M | $-53.5M |
毛利率PDZLAB
| Q4 25 | 85.3% | 51.0% | ||
| Q3 25 | 84.6% | 59.5% | ||
| Q2 25 | 84.0% | 60.6% | ||
| Q1 25 | 83.6% | 63.6% | ||
| Q4 24 | 83.0% | 61.5% | ||
| Q3 24 | 82.7% | 64.1% | ||
| Q2 24 | 82.6% | 64.9% | ||
| Q1 24 | 81.7% | 61.4% |
营业利润率PDZLAB
| Q4 25 | 6.5% | -54.6% | ||
| Q3 25 | 2.9% | -42.3% | ||
| Q2 25 | -8.6% | -50.3% | ||
| Q1 25 | -9.6% | -53.3% | ||
| Q4 24 | -8.7% | -62.6% | ||
| Q3 24 | -13.8% | -66.6% | ||
| Q2 24 | -19.5% | -76.0% | ||
| Q1 24 | -30.1% | -80.7% |
净利率PDZLAB
| Q4 25 | 129.7% | — | ||
| Q3 25 | 7.8% | -31.2% | ||
| Q2 25 | -6.0% | -37.3% | ||
| Q1 25 | -7.2% | -45.8% | ||
| Q4 24 | -5.0% | — | ||
| Q3 24 | -9.4% | -40.9% | ||
| Q2 24 | -15.4% | -80.2% | ||
| Q1 24 | -25.3% | -61.4% |
每股收益（稀释后）PDZLAB
| Q4 25 | $1.69 | $-0.05 | ||
| Q3 25 | $0.10 | $-0.03 | ||
| Q2 25 | $-0.07 | $-0.04 | ||
| Q1 25 | $-0.12 | $-0.04 | ||
| Q4 24 | $-0.07 | $-0.09 | ||
| Q3 24 | $-0.14 | $-0.04 | ||
| Q2 24 | $-0.26 | $-0.08 | ||
| Q1 24 | $-0.34 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $547.8M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $320.5M | $715.5M |
| 总资产 | $1.0B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PDZLAB
| Q4 25 | $547.8M | $689.6M | ||
| Q3 25 | $567.9M | $717.2M | ||
| Q2 25 | $597.1M | $732.2M | ||
| Q1 25 | $570.8M | $757.3M | ||
| Q4 24 | $542.2M | $779.7M | ||
| Q3 24 | $599.3M | $616.1M | ||
| Q2 24 | $592.8M | $630.0M | ||
| Q1 24 | $571.2M | $650.8M |
总债务PDZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $484.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $489.5M | — |
股东权益PDZLAB
| Q4 25 | $320.5M | $715.5M | ||
| Q3 25 | $180.7M | $759.9M | ||
| Q2 25 | $145.7M | $791.7M | ||
| Q1 25 | $129.8M | $810.8M | ||
| Q4 24 | $111.6M | $840.9M | ||
| Q3 24 | $164.7M | $667.7M | ||
| Q2 24 | $174.0M | $704.2M | ||
| Q1 24 | $171.6M | $762.2M |
总资产PDZLAB
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $891.5M | $1.2B | ||
| Q2 25 | $926.8M | $1.2B | ||
| Q1 25 | $927.3M | $1.2B | ||
| Q4 24 | $866.8M | $1.2B | ||
| Q3 24 | $916.0M | $985.3M | ||
| Q2 24 | $924.0M | $987.4M | ||
| Q1 24 | $925.3M | $988.4M |
负债/权益比PDZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.85× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $24.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $24.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 19.3% | -21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.15× | — |
| 过去12个月自由现金流最近4个季度 | $117.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PDZLAB
| Q4 25 | $24.8M | $-26.0M | ||
| Q3 25 | $34.0M | $-32.0M | ||
| Q2 25 | $30.7M | $-31.0M | ||
| Q1 25 | $31.4M | $-61.7M | ||
| Q4 24 | $22.1M | $-55.8M | ||
| Q3 24 | $35.8M | $-26.8M | ||
| Q2 24 | $28.6M | $-42.2M | ||
| Q1 24 | $22.2M | $-90.1M |
自由现金流PDZLAB
| Q4 25 | $24.1M | $-26.7M | ||
| Q3 25 | $33.1M | $-35.0M | ||
| Q2 25 | $30.2M | $-33.9M | ||
| Q1 25 | $30.3M | $-63.2M | ||
| Q4 24 | $21.5M | $-58.4M | ||
| Q3 24 | $35.1M | $-28.2M | ||
| Q2 24 | $28.2M | $-42.9M | ||
| Q1 24 | $21.2M | $-91.1M |
自由现金流率PDZLAB
| Q4 25 | 19.3% | -21.0% | ||
| Q3 25 | 26.8% | -30.4% | ||
| Q2 25 | 25.2% | -31.1% | ||
| Q1 25 | 24.9% | -59.9% | ||
| Q4 24 | 18.1% | -53.8% | ||
| Q3 24 | 30.3% | -27.7% | ||
| Q2 24 | 25.4% | -42.9% | ||
| Q1 24 | 19.1% | -104.5% |
资本支出强度PDZLAB
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 0.4% | 2.6% | ||
| Q1 25 | 0.9% | 1.5% | ||
| Q4 24 | 0.5% | 2.4% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.4% | 0.7% | ||
| Q1 24 | 0.9% | 1.1% |
现金转化率PDZLAB
| Q4 25 | 0.15× | — | ||
| Q3 25 | 3.55× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
